Abstract

POTENTIALITY OF NEWER ORAL ANTI-HYPERGLYCEMIC COMBINATION THERAPY OVER CONVENTIONAL THERAPY

Yerraguntla Hrushi Kesh Reddy* and Lomati Venkata Pavan Kumar Reddy

Abstract

Background: Antidiabetic agents have an important role in normalizing plasma glucose levels. Metformin is now recommended as the first agent for blood glucose lowering in type 2 diabetes patients. However, Monotherapy is capable of maintaining a target glycemic control only for a short term. Effective management requires combination therapy that addresses both insulin resistance and beta cell dysfunction. Patients and Methods: A total of 38 Indian type 2 diabetic patients were enrolled in the study, Patients who were diagnosed with diabetes mellitus and those who were on treatment with glimepiride plus metformin or glibenclamide plus metformin. Results: In the whole group mean FPG decreased during the therapy significantly, from 202.4 ± 31.61 to 153.7 ± 31.88 mg/dL in group-1 and 203.3 ± 39.86 to 147.3 ± 42.56 mg/dL in group-2 Similarly during the therapy HBA1C decreased in group-1 up to -0.90 % and in group-2 up to -1.28%. recduction in Lipid parameters showed in Glimepiride combination therapy. Conclusion: The combination treatment with metformin plus glimepiride was more effective in improving lipid status and reduced the Glycosylated Hemoglobin level, Fasting plasma glucose significantly than the metformin plus glibenclamide treatment.

Keywords: Diabetes, Combination Therapy, Fasting Plasma Glucose, Glycosylated Hemoglobin, Hypoglycemic Agents.